Merus (NASDAQ:MRUS) Shares Purchased by HealthInvest Partners AB

HealthInvest Partners AB boosted its stake in shares of Merus (NASDAQ:MRUS) by 23.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,521 shares of the biotechnology company’s stock after acquiring an additional 11,834 shares during the quarter. Merus comprises 1.2% of HealthInvest Partners AB’s investment portfolio, making the stock its 25th biggest holding. HealthInvest Partners AB owned 0.09% of Merus worth $2,619,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its stake in shares of Merus by 73.6% during the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after purchasing an additional 1,224,573 shares during the last quarter. FMR LLC increased its stake in Merus by 10.4% in the 3rd quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock valued at $343,421,000 after buying an additional 648,994 shares during the period. Westfield Capital Management Co. LP purchased a new position in Merus during the 3rd quarter worth $30,399,000. Lord Abbett & CO. LLC raised its position in Merus by 83.0% during the 3rd quarter. Lord Abbett & CO. LLC now owns 723,988 shares of the biotechnology company’s stock worth $36,171,000 after buying an additional 328,316 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Merus by 7.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company’s stock worth $117,722,000 after acquiring an additional 150,341 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on MRUS shares. The Goldman Sachs Group assumed coverage on shares of Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $85.00 target price on shares of Merus in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. Guggenheim restated a “buy” rating on shares of Merus in a research note on Wednesday, February 12th. Finally, Citigroup upped their price objective on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Merus has a consensus rating of “Buy” and a consensus price target of $85.92.

Merus Stock Down 0.5 %

Merus stock opened at $47.37 on Monday. The firm has a market capitalization of $3.24 billion, a PE ratio of -11.99 and a beta of 1.11. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The firm’s 50-day simple moving average is $41.72 and its 200 day simple moving average is $46.91.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.